ClinicalTrials.gg
CompletedNCT01395758Updated Apr 3, 2018Results posted

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 2 interventional study of ARQ 197 plus erlotinib and Pemetrexed, docetaxel or gemcitabine in Metastatic Non-Small Cell Lung Cancer, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 5 under way, 2 of them phase 3. erlotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
60th of 200
96 · median 58
Started
2011
with 14 others
Phase 2
120 of 203
none open now
Registered
155th of 203
by date

Among the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, this one is the 60th largest by enrollment of the 200 interventional ones that give a count, is one of 15 that started in 2011, is one of 120 in phase 2, and was the 155th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About erlotinib

erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing erlotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate progression-free survival among subjects with KRAS mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib (ARQ 197) compared to single agent chemotherapy.

Read the detailed description

This is a randomized, open-label Phase 2 study designed to compare treatment with erlotinib plus tivantinib (ARQ 197) versus single agent chemotherapy in subjects with previously treated KRAS mutation positive NSCLC. Eligible subjects are randomly assigned to receive erlotinib plus tivantinib or one of three (based on Investigator's choice) single-agent chemotherapy agents including pemetrexed, docetaxel, or gemcitabine.

03

Conditions studied

  • Metastatic Non-Small Cell Lung Cancer

Keywords

  • KRAS mutation
  • metastatic NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide signed and dated prior to study-specific screening procedures
  2. Male or female at least 18 years of age
  3. or cytologically confirmed inoperable locally advanced or (stage IVA/IVB) NSCLC
  4. Documented KRAS mutation positive status (per Lung Cancer Mutation Consortium [LCMC] guidelines; see www.golcmc.com)
  5. At least one prior chemotherapy regimen for advanced NSCLC
  6. as defined by (RECIST) criteria, Version 1.1
  7. (ECOG) performance status 0 to 2
  8. Male or female subjects of child-producing potential must agree to use double barrier , oral contraceptives or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
  9. Females of must have a negative serum pregnancy test
  10. (AST) and alanine transaminase (ALT) ≤ 2.5 × (ULN) or ≤ 5 × ULN with metastatic liver disease
  11. Total ≤ 1.5 × ULN
  12. Serum creatinine ≤ 1.5 × ULN
  13. (ANC) ≥ 1.5 x 10\^9/L
  14. ≥ 100 x 10\^9/L
  15. ≥ 10 g/dL (transfusion is allowed at least 7 days prior to randomization)
  16. Subjects must agree to allow testing for c-Met status if archival and/or fresh tissue samples are available.

Exclusion criteria

Exclusion Criteria:

  1. Previous receipt of erlotinib or other epidermal growth factor receptor (EGFR) inhibitors
  2. Previous receipt of any c-MET inhibitor (a receptor tyrosine kinase) or other c-MET-targeted therapy, including ARQ 197, MetMab, crizotinib
  3. Prior receipt of chemotherapy agent selected for administration in this study (e.g., if subject was treated with gemcitabine, he is not eligible to receive gemcitabine in this study but eligible to receive pemetrexed or docetaxel).
  4. Inability or unwillingness to receive ARQ 197, erlotinib, docetaxel, gemcitabine, and/or pemetrexed including , , or prior administration
  5. Receipt of any anti-tumor treatment for NSCLC within 3 weeks (2 weeks for radiotherapy) prior to randomization
  6. Pregnant or breastfeeding
  7. Significant gastrointestinal disorder that could, in the opinion of the Investigator, interfere with the absorption of ARQ 197 and/or erlotinib
  8. Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation
  9. Other within the last three years, with the exception of adequately treated intraepithelial carcinoma of the cervix uteri, prostate carcinoma with a prostate-specific antigen (PSA) value \< 0.2 ng/mL or basal or squamous cell carcinoma of the skin
  10. Known (HIV), or active virus (HBV) or virus (HCV) infection
  11. Major surgical procedure within 4 weeks prior to randomization
  12. History of cardiac disease: Congestive heart failure defined as Class II to IV per classification; Active coronary artery disease; Previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ Grade 2 according to National Cancer Institute (NCI) (CTCAE), version 4.0, or uncontrolled hypertension; Myocardial infarction that occurred within 6 months prior to study entry (myocardial infarction that occurred > 6 months prior to study entry is permitted)
  13. Clinically unstable central nervous system (to be enrolled in the study, subjects must have confirmation of stable disease by MRI or CT scan within 4 weeks of randomization and have central nervous system [CNS] metastases well controlled by , anti-epileptics or other symptom-relieving medications)
  14. Known EGFR-mutation positive status
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    tivantinib (ARQ 197) plus erlotinib arm

    Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197). Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

    Drug: ARQ 197 plus erlotinib

  • Active comparator
    Chemotherapy arm

    Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.

    Drug: Pemetrexed, docetaxel or gemcitabine

Interventions

  • DrugARQ 197 plus erlotinib

    Drug pages: ARQ 197Studies of ARQ 197ARQ 197 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ErlotinibStudies of ErlotinibErlotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.

    Also known as: Tivantinib

  • DrugPemetrexed, docetaxel or gemcitabine

    Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.

    Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) criteria as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or progression of existing non-target lesions are also considered progression.

    Time frame: Date of randomization until disease progression per RECIST (v 1.1) or death from any cause, whichever came first, assessed up to 24 months.

Secondary outcomes

  1. Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.

    OS is calculated from the date of randomization until death from any cause.

    Time frame: Date of randomization to the date of death from any cause, assessed up to 24 months

  2. Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.

    Per RECIST v1.1, Complete Response (CR) = disappearance of all lesions and Partial Response (PR) = at least 30% decrease in the sum of diameters of target lesions. ORR = (CR+PR)/# subjects.

    Time frame: Date of randomization to the date of death from any cause or to the date that the subject discontinues from the study, assessed up to 24 months

  3. ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib

    Per RECIST v1.1, CR = disappearance of all lesions and PR = at least 30% decrease in the sum of diameters of target lesions. ORR = (CR+PR)/# subjects.

    Time frame: Date of randomization to the date of death from any cause or to the date that the subject discontinues from the study, assessed up to 24 months.

07

Results

Posted Apr 3, 2018

Participant flow

Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestoneTivantinib Plus Erlotinib ArmChemotherapy ArmCrossover Arm
Started51450
Completed47450
Not completed400
Withdrew: Withdrawal by subject400
Crossover Period
Participant flow — Crossover Period
MilestoneTivantinib Plus Erlotinib ArmChemotherapy ArmCrossover Arm
Started0026
Completed0026
Not completed000

Outcome measures

PrimaryProgression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.

Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) criteria as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions or progression of existing non-target lesions are also considered progression.

Time frame:
Date of randomization until disease progression per RECIST (v 1.1) or death from any cause, whichever came first, assessed up to 24 months.
Reported as:
Median · weeks
Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.
weeksTivantinib Plus Erlotinib ArmChemotherapy Arm
Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.7.3 (6.86 to 24.14)18.6 (7.0 to 25.0)
Statistical analysis
  • Tivantinib Plus Erlotinib Arm vs Chemotherapy Arm · Log Rank · p = 0.5017
SecondaryOverall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.

OS is calculated from the date of randomization until death from any cause.

Time frame:
Date of randomization to the date of death from any cause, assessed up to 24 months
Reported as:
Median · months
Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.
monthsTivantinib Plus Erlotinib ArmChemotherapy Arm
Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.6.8 (4.97 to 10.70)8.5 (6.37 to 13.97)
Statistical analysis
  • Tivantinib Plus Erlotinib Arm vs Chemotherapy Arm · Log Rank · p = 0.4356
SecondaryObjective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.

Per RECIST v1.1, Complete Response (CR) = disappearance of all lesions and Partial Response (PR) = at least 30% decrease in the sum of diameters of target lesions. ORR = (CR+PR)/# subjects.

Time frame:
Date of randomization to the date of death from any cause or to the date that the subject discontinues from the study, assessed up to 24 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.
ParticipantsTivantinib Plus Erlotinib ArmChemotherapy Arm
Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.04
SecondaryORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib

Per RECIST v1.1, CR = disappearance of all lesions and PR = at least 30% decrease in the sum of diameters of target lesions. ORR = (CR+PR)/# subjects.

Time frame:
Date of randomization to the date of death from any cause or to the date that the subject discontinues from the study, assessed up to 24 months.
Reported as:
Count of participants · Participants
ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib
ParticipantsTivantinib Plus Erlotinib Crossover Period
ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib2

Adverse events

Collected over Adverse event data were collected from the date of the first dose of study drug and up to 30 days after the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tivantinib Plus Erlotinib Arm3/51 (5.9%)19/51 (37.3%)51/51 (100%)
Chemotherapy Arm4/45 (8.9%)25/45 (55.6%)45/45 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventTivantinib Plus Erlotinib ArmChemotherapy Arm
Febrile neutropeniaBlood and lymphatic system disorders0/514/45
Disease progressionGeneral disorders3/514/45
PneumoniaInfections and infestations4/514/45
Pleural effusionRespiratory, thoracic and mediastinal disorders3/510/45
AnaemiaBlood and lymphatic system disorders0/512/45
Urinary tract infectionInfections and infestations0/512/45
DehydrationMetabolism and nutrition disorders2/512/45
DyspnoeaRespiratory, thoracic and mediastinal disorders2/512/45
PneumonitisRespiratory, thoracic and mediastinal disorders0/512/45
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/512/45
Most frequent other events
Showing 10 of 290
Most frequent other events
EventTivantinib Plus Erlotinib ArmChemotherapy Arm
FatigueGeneral disorders23/5126/45
AnaemiaBlood and lymphatic system disorders22/5122/45
NauseaGastrointestinal disorders17/5121/45
DiarrhoeaGastrointestinal disorders22/5114/45
RashSkin and subcutaneous tissue disorders22/517/45
NeutropeniaBlood and lymphatic system disorders3/5116/45
Decreased appetiteMetabolism and nutrition disorders17/5116/45
CoughRespiratory, thoracic and mediastinal disorders16/5110/45
DyspnoeaRespiratory, thoracic and mediastinal disorders12/5114/45
ConstipationGastrointestinal disorders14/5111/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
<=18 years000
Between 18 and 65 years281644
>=65 years232952
Age, Continuous
Age, Continuous(years)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
Mean62.6 ± 9.2365.2 ± 9.5563.8 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
Female333063
Male181533
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
Hispanic or Latino101
Not Hispanic or Latino504595
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American123
White474188
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
United States514596
Cigarette Use
Cigarette Use(Participants)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
Yes464288
No538
Weight
Weight(kilograms)Tivantinib Plus Erlotinib ArmChemotherapy ArmTotal
Mean72.50 ± 17.3168.86 ± 15.1970.79 ± 16.37

3 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Stanford, California 94305, United States
  • Washington, District of Columbia 20057, United States
  • Weston, Florida 33331, United States
  • Atlanta, Georgia 30341, United States
  • Chicago, Illinois 60611, United States
  • Kansas City, Kansas 66160, United States
  • Baltimore, Maryland 21205, United States
  • Boston, Massachusetts 02114, United States
  • Burlington, Massachusetts 01805, United States
  • New York, New York 10016, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Charleston, South Carolina 29425, United States
  • Dallas, Texas 75390, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2011
First posted
Jul 18, 2011
Start
Jul 2011
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results first posted
Apr 3, 2018
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01395758
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Jul 2011
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Apr 3, 2018
Last update
Apr 3, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ARQ 197 · Erlotinib

Start the discussion